Skip to main content

Advertisement

SpringerLink
Log in

Molecular markers in colorectal cancer: genetic bases for a customised treatment

  • Educational Series
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer death in Western countries. CRC treatment is based on the employment of three chemotherapeutic drugs, including 5-fluorouracil, oxaliplatin and irinotecan, and the use of recently incorporated targeted agents directed to vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). The approval of these biologicals and of others to come holds great promise for the improvement of patient outcome. The molecular bases for this lethal disease have been extensively investigated, laying the foundations for a rational and customised treatment approach, expanding the therapeutic index of current drugs and easing the incorporation of new molecules. Individual markers have been mainly investigated based on drug targets and metabolism. Also, the increasing availability of high-throughput technologies has prompted the opportunity for blind studies capable of screening new markers and of identifying the specific oncogenic pathways responsible for drug resistance in a given patient. An updated review of the field is presented in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66, 2007.

    Article  PubMed  Google Scholar 

  2. Andre T, Tournigand C, Mineur L et al (2007) Phase II study of an optimized 5-fluorouraciloxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Ann Oncol 18:77–81

    Article  PubMed  CAS  Google Scholar 

  3. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  4. Van Cutsem E (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J Clin Oncol 25 (Abstract)

  5. Fearon ER, Pardoll DM, Itaya T et al (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403

    Article  PubMed  CAS  Google Scholar 

  6. Habermann JK, Paulsen U, Roblick UJ et al (2007) Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 46:10–26

    Article  PubMed  CAS  Google Scholar 

  7. Kinzler KW, Vogelstein B (1998) Landscaping the cancer terrain. Science 280:1036–1037

    Article  PubMed  CAS  Google Scholar 

  8. Rak J, Mitsuhashi Y, Bayko L et al (1995) Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575–4580

    PubMed  CAS  Google Scholar 

  9. Allegra CJ, Paik S, Colangelo LH et al (2003) Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241–250

    Article  PubMed  CAS  Google Scholar 

  10. Lenz HJ, Hayashi K, Salonga D et al (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250

    PubMed  CAS  Google Scholar 

  11. Edler D, Glimelius B, Hallstrom M et al (2002) Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:1721–1728

    Article  PubMed  CAS  Google Scholar 

  12. Pullarkat ST, Stoehlmacher J, Ghaderi V et al (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70

    PubMed  CAS  Google Scholar 

  13. Marsh S, McKay JA, Cassidy J, McLeod HL (2001) Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383–386

    PubMed  CAS  Google Scholar 

  14. Villafranca E, Okruzhnov Y, Dominguez MA et al (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779–1786

    PubMed  CAS  Google Scholar 

  15. Johnston PG, Benson AB III, Catalano P et al (2003) Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. J Clin Oncol 21:815–819

    Article  PubMed  CAS  Google Scholar 

  16. Lyss AP, Lilenbaum RC, Harris BE, Diasio RB (1993) Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 11:239–240

    Article  PubMed  CAS  Google Scholar 

  17. Metzger R, Danenberg K, Leichman CG et al (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371–2376

    PubMed  CAS  Google Scholar 

  18. Salonga D, Danenberg KD, Johnson M et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327

    PubMed  CAS  Google Scholar 

  19. Smorenburg CH, Peters GJ, van Groeningen CJ et al (2006) Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 17:35–42

    Article  PubMed  CAS  Google Scholar 

  20. Westra JL, Hollema H, Schaapveld M et al (2005) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 16:1646–1653

    Article  PubMed  CAS  Google Scholar 

  21. Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257

    Article  PubMed  CAS  Google Scholar 

  22. Elsaleh H, Joseph D, Grieu F et al (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355:1745–1750

    Article  PubMed  CAS  Google Scholar 

  23. Allegra CJ, Kim G, Kirsch IR (2003) Microsatellite instability in colon cancer. N Engl J Med 349:1774–1776

    Article  PubMed  CAS  Google Scholar 

  24. Li XG, Haluska P Jr, Hsiang YH et al (1996) Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin. Ann N Y Acad Sci 803:111–127

    Article  PubMed  CAS  Google Scholar 

  25. Marcuello E, Altes A, Menoyo A et al (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678–682

    PubMed  CAS  Google Scholar 

  26. Goetz MP, Reid JM, Safgren SL et al. UGT1A1*28 genotype determines the maximum associated tolerated dose and pharmacokinetics of irinotecan-based chemotherapy: a phase I dose-escalation trial. Proceedings of the 2007 GI Cancers Symposium, abst. 235.

  27. Fallik D, Borrini F, Boige V et al (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63:5738–5744

    PubMed  CAS  Google Scholar 

  28. Stoehlmacher J, Park DJ, Zhang W et al (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942

    PubMed  CAS  Google Scholar 

  29. Arnould S, Hennebelle I, Canal P et al (2003) Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39:112–119

    Article  PubMed  CAS  Google Scholar 

  30. Shirota Y, Stoehlmacher J, Brabender J et al (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304

    PubMed  CAS  Google Scholar 

  31. Stoehlmacher J, Ghaderi V, Iobal S et al (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21: 3075–3079

    PubMed  CAS  Google Scholar 

  32. Hayward RL, Macpherson JS, Cummings J et al (2004) Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 3:169–178

    PubMed  CAS  Google Scholar 

  33. Bunz F, Hwang PM, Torrance C et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269

    Article  PubMed  CAS  Google Scholar 

  34. Zhang L, Yu J, Park BH et al (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290:989–992

    Article  PubMed  CAS  Google Scholar 

  35. Longley DB, Wilson TR, McEwan M et al (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25:838–848

    Article  PubMed  CAS  Google Scholar 

  36. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365

    Article  PubMed  CAS  Google Scholar 

  37. Hebbar M, Wacrenier A, Desauw C et al (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17:855–857

    Article  PubMed  CAS  Google Scholar 

  38. Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286

    Article  PubMed  CAS  Google Scholar 

  39. Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995

    Article  PubMed  CAS  Google Scholar 

  40. Zhang W, Gordon M, Schultheis AM et al (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712–3718

    Article  PubMed  CAS  Google Scholar 

  41. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544

    Article  PubMed  CAS  Google Scholar 

  42. Lenz HJ. Can we predict response to EGFR and VEGF inhibitors?. Proceedings of the 9th World Congress on Gastrointestinal Cancer (pgs 271–2)

  43. Downward J (2006) Cancer biology: signatures guide drug choice. Nature 439:274–275

    Article  PubMed  CAS  Google Scholar 

  44. Mariadason JM, Arango D, Shi Q et al (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63:8791–8812

    PubMed  CAS  Google Scholar 

  45. Bertucci F, Salas S, Eysteries S et al (2004) Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23:1377–1391

    Article  PubMed  CAS  Google Scholar 

  46. Wang Y, Jatkoe T, Zhang Y et al (2004) Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 22:1564–1571

    Article  PubMed  CAS  Google Scholar 

  47. Barrier A, Lemoine A, Boelle PY et al (2005) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24:6155–6164

    Article  PubMed  CAS  Google Scholar 

  48. Del RM, Molina F, Bascoul-Mollevi C et al (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 25:773–780

    Article  CAS  Google Scholar 

  49. Ghadimi BM, Grade M, Difilippantonio MJ et al (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826–1838

    Article  PubMed  CAS  Google Scholar 

  50. Watanabe T, Komuro Y, Kiyomatsu T et al (2006) Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 66:3370–3374

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departamento de Oncología Médica Translational Oncology Unit, Hospital Universitario La Paz Universidad Autónoma de Madrid, Madrid, Spain

    E. Casado, J. De Castro, C. Belda-Iniesta, P. Cejas, J. Feliu, M. Sereno & M. González-Barón

Authors
  1. E. Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. De Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Belda-Iniesta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Cejas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Feliu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Sereno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. González-Barón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Casado.

Additional information

Supported by an unrestricted educational grant from Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Casado, E., De Castro, J., Belda-Iniesta, C. et al. Molecular markers in colorectal cancer: genetic bases for a customised treatment. Clin Transl Oncol 9, 549–554 (2007). https://doi.org/10.1007/s12094-007-0102-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0102-8

Key words

Search

Navigation